DE19627344A1 - Therapeutic composition containing epicatechin and/or theaflavin - Google Patents
Therapeutic composition containing epicatechin and/or theaflavinInfo
- Publication number
- DE19627344A1 DE19627344A1 DE19627344A DE19627344A DE19627344A1 DE 19627344 A1 DE19627344 A1 DE 19627344A1 DE 19627344 A DE19627344 A DE 19627344A DE 19627344 A DE19627344 A DE 19627344A DE 19627344 A1 DE19627344 A1 DE 19627344A1
- Authority
- DE
- Germany
- Prior art keywords
- preparation according
- therapy
- prophylaxis
- theaflavin
- hiv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- IPMYMEWFZKHGAX-UHFFFAOYSA-N Isotheaflavin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(C1=C2)=CC(O)=C(O)C1=C(O)C(=O)C=C2C1C(O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-UHFFFAOYSA-N 0.000 title claims abstract description 6
- UXRMWRBWCAGDQB-UHFFFAOYSA-N Theaflavin Natural products C1=CC(C2C(CC3=C(O)C=C(O)C=C3O2)O)=C(O)C(=O)C2=C1C(C1OC3=CC(O)=CC(O)=C3CC1O)=CC(O)=C2O UXRMWRBWCAGDQB-UHFFFAOYSA-N 0.000 title claims abstract description 5
- 235000014620 theaflavin Nutrition 0.000 title claims abstract description 5
- IPMYMEWFZKHGAX-ZKSIBHASSA-N theaflavin Chemical compound C1=C2C([C@H]3OC4=CC(O)=CC(O)=C4C[C@H]3O)=CC(O)=C(O)C2=C(O)C(=O)C=C1[C@@H]1[C@H](O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-ZKSIBHASSA-N 0.000 title claims abstract description 5
- 229940026509 theaflavin Drugs 0.000 title claims abstract description 5
- 239000000203 mixture Substances 0.000 title claims abstract 6
- 230000001225 therapeutic effect Effects 0.000 title claims description 5
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 title claims 2
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 title 1
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 title 1
- 235000012734 epicatechin Nutrition 0.000 title 1
- 244000269722 Thea sinensis Species 0.000 claims abstract description 29
- 239000003814 drug Substances 0.000 claims abstract description 7
- 239000000284 extract Substances 0.000 claims abstract description 7
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims abstract description 6
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims abstract description 6
- 235000006468 Thea sinensis Nutrition 0.000 claims abstract description 5
- GPLOTACQBREROW-UHFFFAOYSA-N Phlegmanol A-acetat Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(=CC1=2)C=C(O)C(=O)C1=C(O)C(O)=CC=2C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 GPLOTACQBREROW-UHFFFAOYSA-N 0.000 claims abstract 4
- KMJPKUVSXFVQGZ-WQLSNUALSA-N [(2r,3r)-5,7-dihydroxy-2-[3,4,5-trihydroxy-6-oxo-1-[(2r,3r)-3,5,7-trihydroxy-3,4-dihydro-2h-chromen-2-yl]benzo[7]annulen-8-yl]-3,4-dihydro-2h-chromen-3-yl] 3,4,5-trihydroxybenzoate Chemical compound O([C@@H]1CC2=C(O)C=C(O)C=C2O[C@@H]1C1=CC(=O)C(O)=C2C(O)=C(O)C=C(C2=C1)[C@H]1OC2=CC(O)=CC(O)=C2C[C@H]1O)C(=O)C1=CC(O)=C(O)C(O)=C1 KMJPKUVSXFVQGZ-WQLSNUALSA-N 0.000 claims abstract 4
- FJYGFTHLNNSVPY-BBXLVSEPSA-N theaflavin digallate Chemical compound C1=C([C@@H]2[C@@H](CC3=C(O)C=C(O)C=C3O2)O)C=C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(=O)C2=C1C([C@H]1OC3=CC(O)=CC(O)=C3C[C@H]1O)=CC(O)=C2OC(=O)C1=CC(O)=C(O)C(O)=C1 FJYGFTHLNNSVPY-BBXLVSEPSA-N 0.000 claims abstract 3
- 238000002360 preparation method Methods 0.000 claims description 39
- 238000011321 prophylaxis Methods 0.000 claims description 26
- 238000002560 therapeutic procedure Methods 0.000 claims description 25
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 9
- 239000003963 antioxidant agent Substances 0.000 claims description 9
- 235000006708 antioxidants Nutrition 0.000 claims description 9
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 5
- 230000003078 antioxidant effect Effects 0.000 claims description 5
- 238000001784 detoxification Methods 0.000 claims description 5
- LSHVYAFMTMFKBA-UHFFFAOYSA-N ECG Natural products C=1C=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-UHFFFAOYSA-N 0.000 claims description 4
- 206010063493 Premature ageing Diseases 0.000 claims description 4
- 208000032038 Premature aging Diseases 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 230000006378 damage Effects 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 230000009467 reduction Effects 0.000 claims description 4
- 150000003626 triacylglycerols Chemical class 0.000 claims description 4
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 claims description 3
- 208000035473 Communicable disease Diseases 0.000 claims description 3
- 206010012735 Diarrhoea Diseases 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 3
- 230000000923 atherogenic effect Effects 0.000 claims description 3
- 230000035622 drinking Effects 0.000 claims description 3
- 238000001631 haemodialysis Methods 0.000 claims description 3
- 230000000322 hemodialysis Effects 0.000 claims description 3
- 230000007124 immune defense Effects 0.000 claims description 3
- 208000027866 inflammatory disease Diseases 0.000 claims description 3
- 208000019423 liver disease Diseases 0.000 claims description 3
- 230000036542 oxidative stress Effects 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 238000011282 treatment Methods 0.000 claims description 3
- 208000030507 AIDS Diseases 0.000 claims description 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims description 2
- 241000196324 Embryophyta Species 0.000 claims description 2
- 241000792859 Enema Species 0.000 claims description 2
- 101900297506 Human immunodeficiency virus type 1 group M subtype B Reverse transcriptase/ribonuclease H Proteins 0.000 claims description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 206010027476 Metastases Diseases 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 2
- 230000037396 body weight Effects 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 230000001413 cellular effect Effects 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 239000000824 cytostatic agent Substances 0.000 claims description 2
- 230000001085 cytostatic effect Effects 0.000 claims description 2
- 235000015872 dietary supplement Nutrition 0.000 claims description 2
- 239000008298 dragée Substances 0.000 claims description 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 2
- 239000007920 enema Substances 0.000 claims description 2
- 229940095399 enema Drugs 0.000 claims description 2
- 239000007941 film coated tablet Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 230000035987 intoxication Effects 0.000 claims description 2
- 231100000566 intoxication Toxicity 0.000 claims description 2
- 201000006370 kidney failure Diseases 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 239000007858 starting material Substances 0.000 claims description 2
- 230000003319 supportive effect Effects 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 claims 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-3',4',5,7-Tetrahydroxy-2,3-trans-flavan-3-ol Natural products C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims 1
- 229930013783 (-)-epicatechin Natural products 0.000 claims 1
- 235000007355 (-)-epicatechin Nutrition 0.000 claims 1
- 102000029797 Prion Human genes 0.000 claims 1
- 108091000054 Prion Proteins 0.000 claims 1
- 208000002925 dental caries Diseases 0.000 claims 1
- 235000005911 diet Nutrition 0.000 claims 1
- 230000037213 diet Effects 0.000 claims 1
- 230000002500 effect on skin Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 230000037356 lipid metabolism Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 210000002845 virion Anatomy 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 238000000605 extraction Methods 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 235000009569 green tea Nutrition 0.000 description 20
- 235000013824 polyphenols Nutrition 0.000 description 14
- 150000008442 polyphenolic compounds Chemical class 0.000 description 13
- 230000000694 effects Effects 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 235000013616 tea Nutrition 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 235000020688 green tea extract Nutrition 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 102100034343 Integrase Human genes 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 235000020279 black tea Nutrition 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- 229940030275 epigallocatechin gallate Drugs 0.000 description 3
- 150000002206 flavan-3-ols Chemical class 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- -1 polyphenol compounds Chemical class 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 239000000717 tumor promoter Substances 0.000 description 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- CITFYDYEWQIEPX-UHFFFAOYSA-N Flavanol Natural products O1C2=CC(OCC=C(C)C)=CC(O)=C2C(=O)C(O)C1C1=CC=C(O)C=C1 CITFYDYEWQIEPX-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 2
- 230000003217 anti-cancerogenic effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 235000013734 beta-carotene Nutrition 0.000 description 2
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 2
- 239000011648 beta-carotene Substances 0.000 description 2
- 229960002747 betacarotene Drugs 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 231100000357 carcinogen Toxicity 0.000 description 2
- 239000003183 carcinogenic agent Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 235000006694 eating habits Nutrition 0.000 description 2
- 235000011987 flavanols Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000000340 Glucosyltransferases Human genes 0.000 description 1
- 108010055629 Glucosyltransferases Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 206010029098 Neoplasm skin Diseases 0.000 description 1
- 102000052812 Ornithine decarboxylases Human genes 0.000 description 1
- 108700005126 Ornithine decarboxylases Proteins 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- QOLIPNRNLBQTAU-UHFFFAOYSA-N flavan Chemical compound C1CC2=CC=CC=C2OC1C1=CC=CC=C1 QOLIPNRNLBQTAU-UHFFFAOYSA-N 0.000 description 1
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 238000007034 nitrosation reaction Methods 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 235000011875 whole grain product Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Botany (AREA)
- Medicinal Chemistry (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Therapeutisch wirksame bzw. gesundheitsfördernde Zubereitung aus definierten Polyphenolverbindungen.Therapeutically effective or health-promoting preparation from defined polyphenol compounds.
Reduktions- und Oxidationsvorgänge finden in jeder Zelle statt und sorgen dafür, daß Lebewesen chemisch gebundene Energie nutzen können.Reduction and oxidation processes take place in every cell and ensure that Living beings can use chemically bound energy.
Bei der Energiegewinnung in der Zelle wird Sauerstoff in verschiedene chemische Verbin dungen umgesetzt, auch in sogenannte freie Radikale. Freie Radikale sind sehr reaktions freudig und können Kettenreaktionen auslösen, die zu Schädigungen von biologischen Strukturen wie der Zellmembranen und/oder der DNA führen können.When generating energy in the cell, oxygen is compounded into various chemical compounds implemented in so-called free radicals. Free radicals are very reactive joyful and can trigger chain reactions that damage biological Structures such as cell membranes and / or DNA can result.
Die pathophysiologische Rolle der freien Radikale ist in letzter Zeit Gegenstand intensiver Forschung. Nach dem gegenwärtigen Stand der Erkenntnisse haben freie Radikale Einfluß auf Entstehung und Verlauf vonThe pathophysiological role of free radicals has recently been the subject of more intense research Research. According to the current state of knowledge, free radicals have an impact on the origin and course of
- - Krebserkrankungen- cancer
- - Rheuma- rheumatism
- - Arteriosklerose- atherosclerosis
- - Immunabwehrstörungen- immune defense disorders
- - Hepatopathien- hepatopathies
- - entzündlichen Erkrankungen jeder Genese- inflammatory diseases of any genesis
- - Schäden an biologischen Strukturen- Damage to biological structures
- - Infektionserkrankungen jeder Genese.- Infectious diseases of any genesis.
Um die negative Wirkung der freien Radikale aufzuhalten, bzw. zu verlangsamen, werden Antioxidantien im Organismus benötigt. Die körpereigenen Schutzsysteme gegen freie Radikale verlieren bei Belastungen durch Erkrankungen, Sport. Umweltbedingungen und mit fortschreitendem Lebensalter an Effizienz, daher bedürfen sie der gezielten Unterstützung von außen. Prophylaxe ist möglich durch regelmäßige Aufnahme bestimmter Lebens mittel, die ggf. durch Antioxidantien angereichert sind. Die wichtigsten bisher erforschten Stoffe zur Radikalentgiftung finden sich in Lebensmitteln, z. B. die Vitamine C und E. Caroti noide, Selen.To stop or slow down the negative effects of free radicals Antioxidants needed in the organism. The body's protective systems against free Radicals lose when burdened by illness, sport. Environmental conditions and with advancing age in efficiency, therefore they need the targeted support from the outside. Prophylaxis is possible through regular intake of certain life agents that may be enriched with antioxidants. The most important ones researched so far Radical detoxification substances can be found in foods, e.g. B. Vitamins C and E. Caroti noide, selenium.
Besondere Bedeutung als Antioxidantien erlangen in der letzten Zeit sogenannte Phytochemikalien (z. B. Polyphenole), wie sie etwa in bestimmten Beerenarten, Knoblauch, Zitrusfrüchten. Sojabohnen und im Grüntee vorkommen:So-called antioxidants have recently become particularly important Phytochemicals (e.g. polyphenols), such as those found in certain types of berries, garlic, Citrus. Soybeans and green tea:
Unterschiedliche Lebensgewohnheiten in verschiedenen Kulturkreisen etwa im Vergleich zwischen Asien und Europa spiegeln sich wesentlich im Ernährungsverhalten wider. Daraus ergeben sich bezüglich der regelmäßigen Aufnahme antioxidantienreicher Lebens mittel große Unterschiede im Vergleich verschiedener Kulturkreise.Different living habits in different cultures, for example, in comparison between Asia and Europe are largely reflected in their eating habits. This results in the regular intake of antioxidant-rich life medium-sized differences in the comparison of different cultures.
Ein ähnlicher Effekt ergibt sich auch durch krankheitsbedingt eingeschränkte Nahrungs auswahl. Hinsichtlich der Inzidenz einiger Krankheitsbilder bzw. prognostischer Risikofaktoren bestehen hochsignifikante Korrelationen zu spezifischen Ernährungsgewohnheiten.A similar effect also results from restricted food due to illness selection. With regard to the incidence of some clinical pictures or prognostic risk factors there are highly significant correlations with specific eating habits.
In einer japanischen Querschnittsstudie an 1371 Männern ergaben sich verringerte Serumcholesterol und -triglyceridwerte, ein verringerter atherogener Index sowie verbes serte Leberwerte durch den regelmäßigen Genuß von grünem Tee. Die besten Werte wurden bei einer täglichen Aufnahme von mindestens zehn Tassen Grüntee beobachtet.In a Japanese cross-sectional study of 1,371 men, there were reduced Serum cholesterol and triglyceride levels, a reduced atherogenic index and verbes Conserve liver values through the regular consumption of green tea. The best values were observed with a daily intake of at least ten cups of green tea.
Die Krebs-Inzidenz in Ländern mit hohem Grüntee-Konsum (Japan.China) ist geringer als etwa in Mitteleuropa.The cancer incidence in countries with high green tea consumption (Japan.China) is less than for example in Central Europe.
Langzeitdialysepatienten (HD=Hämodialyse) haben im Ergebnis einer 13-Jahres-Studie ein signifikant höheren Risiko, an einem Tumorleiden zu erkranken.Long-term dialysis patients (HD = hemodialysis) have a result of a 13-year study significantly higher risk of developing cancer.
HD-Patienten haben eine geringe Antioxidantienzufuhr, da grüne Gemüse und Vollkornprodukte, die β-Carotin und Vitamin E enthalten, wegen des hohen Kaliumgehaltes kaum verzehrt werden dürfen.HD patients have a low antioxidant intake because of green vegetables and Whole grain products that contain β-carotene and vitamin E because of their high potassium content can hardly be consumed.
HD-Patienten haben eine geringe Selenzufuhr und einen niedrigen Seien-Status. In Vitaminpräparaten für HD-Patienten ist β-Carotin und Vitamin E nicht enthalten, da die Gefahr der Akkumulation besteht. Nur wasserlösliche Vitamine werden substituiert. Die tägliche Flüssigkeitszufuhr ist für HD-Patienten streng limitiert auf 500-800 ml plus Rest diurese. Zum Ausgleich dieses Antioxidantiendefizites bei HD-Patienten bieten sich wasser lösliche, nichtflüssige Polyphenol-haltige Zubereitungen an, z. B. aus grünem Tee.HD patients have a low selenium intake and a low status. Vitamin preparations for HD patients do not contain β-carotene and vitamin E, because the There is a risk of accumulation. Only water-soluble vitamins are substituted. The daily fluid intake for HD patients is strictly limited to 500-800 ml plus rest diuresis. To compensate for this deficiency in antioxidants in HD patients, water is available soluble, non-liquid polyphenol-containing preparations, e.g. B. from green tea.
Für folgende Bereiche wurde die Wirkung von Grünteeextrakt oder isolierten Einzelstoffen in Versuchen gezeigt.For the following areas, the effect of green tea extract or isolated individual substances in Try shown.
In einem Mehrstufen Modell wurde die tumorhemmende Wirkung von Grünteeextrakten und isolierten Einzelstoffen an der Maus und der Ratte gezeigt. Bei Hauttumoren, Mammatumoren, Tumoren des Vormagens, der Lunge, der Speiseröhre, des Dünndarms und des Darms konnten Schutzeffekte zwischen 31 und 95% erzielt werden.The tumor-inhibiting effect of green tea extracts was tested in a multi-stage model and isolated individual substances on the mouse and the rat. With skin tumors, Breast tumors, tumors of the forestomach, the lungs, the esophagus, the Protective effects of between 31 and 95% could be achieved in the small intestine and intestine.
An Zellkulturen wurde die Hemmung der Infektiosität von Influenza A- und -B-Viren ermittelt. Epigallocatechingallat und Epicatechingallat hemmt die reverse Transcriptase von HIV.The inhibition of the infectivity of influenza A and B viruses was carried out on cell cultures determined. Epigallocatechin gallate and epicatechin gallate inhibit reverse transcriptase from HIV.
Grünteeextrakte, Theaflavin und Epigallochatechingallat hemmen die Glukosyltransferase des plaquebildenden Enzyms von Streptococcus mutans.Green tea extracts, theaflavin and epigallochatechin gallate inhibit the Streptococcus mutans plaque-forming enzyme glucosyltransferase.
Tee-Extrakte wirken auf verschiedene Durchfallerreger bakterizid und inaktivieren das Toxin von Vibrio cholerae. Tea extracts have a bactericidal effect on various diarrhea pathogens and inactivate it Vibrio cholerae toxin.
Grünteeextrakte senken bei Ratten die Triglyceride. Für Epicatechingallat und Epigallocatechingallat wurde eine cholesterinsenkende Wirkung und Hemmung der LDL-Oxidation im Tierversuch gefunden, in einer epidemiologischen Studie an 1300 Männern wurde die senkende Wirkung auf Gesamtcholesterin, LDL und Triglyceride und ein HDL- steigernder Effekt gezeigt. LDL-Peroxide wurden unter Grüntee in geringerem Maße nachgewiesen.Green tea extracts lower the triglycerides in rats. For epicatechin gallate and Epigallocatechin gallate has been shown to lower cholesterol and inhibit the LDL oxidation found in animal experiments, in an epidemiological study in 1300 men the lowering effect on total cholesterol, LDL and triglycerides and an HDL increasing effect shown. LDL peroxides were less common among green tea proven.
In der oben angeführten Studie ergab sich eine Senkung der Aspartat-Aminotransferase und Alanintransferase, die eine Leberschädigung anzeigen.The above study showed a decrease in aspartate aminotransferase and alanine transferase, which indicate liver damage.
Bluthochdruck, durch Adenin induziert, konnte bei Ratten nach Grünteegabe gesenkt
werden.
Kollagen und Thrombin induzierte Blutplättchenaggregation wird durch
Epigallocatechingallat vollständig gehemmt.Hypertension induced by adenine could be reduced in rats after green tea.
Collagen and thrombin-induced platelet aggregation is completely inhibited by epigallocatechin gallate.
Bei Ratten konnte durch einen Grünteeextrakt der Blutzuckerspiegel von Streptozotocindiabetisierten Ratten gesenkt werden.In green rats, the blood sugar level of Streptozotocin-diabetic rats are lowered.
Allgemeine Empfehlungen zur Umstellung der Trinkgewohnheiten z. B. auf Grüntee hin sichtlich der nahezu ausschließlichen Deckung der täglichen Flüssigkeitszufuhr sind in Mitteleuropa kaum durchsetzbar. Daraus ergibt sich in der vorliegenden Erfindung die Erfindungshöhe in dem Ansatz, die wirksamen Prinzipien vorwiegend pflanzlichen Ausgangsmaterials, z. B. Polyphenole des Grüntees, in verbrauchergerechter Zubereitung allgemein zugänglich zu machen. Im wesentlichen kommen hier Zubereitungen aus Grüntee in Betracht, da diese über einen hohen Anteil an wirkungsrelevanten Inhaltsstoffen (Polyphenole) verfügen.General recommendations for changing your drinking habits, e.g. B. towards green tea the almost exclusive coverage of the daily fluid intake are in Central Europe hardly enforceable. This results in the present invention Inventiveness in the approach, the effective principles predominantly vegetable Starting material, e.g. B. Polyphenols of green tea, in a consumer-friendly preparation generally accessible. Essentially, preparations come from here Green tea should be considered as it contains a high proportion of ingredients that are relevant to the effects (Polyphenols).
Im einzelnen werden die Zubereitungen gefertigt z. B. alsIn detail, the preparations are made e.g. B. as
- - Pulver in abgeteilter und nicht abgeteilter Form- Powder in divided and undivided form
- - Granulat- granules
- - Suspension- suspension
- - Tablette- Tablet
- - Filmtablette- film-coated tablet
- - Kapsel- capsule
- - Dragee- Dragee
- - Lösung zur enteralen und parenteralen Applikation- Solution for enteral and parenteral application
- - Extrakt- extract
- - Pulverextrakt zur Bereitung einer Trinklösung- Powder extract for the preparation of a drinking solution
- - Suppositorium- suppository
- - Klistier- Enema
- - Salbe/Creme/Gel.Ointment / cream / gel.
Bei der Herstellung der oben bezeichneten Darreichungsformen der erfindungsgemäßen Zubereitungen kommen die jeweils aktuellen Verfahrensrichtlinien der Lebensmitteltechno logie bzw. der Pharmazeutischen Technologie zum Einsatz, hinsichtlich der Auswahl geeigneter und zugelassener Hilfs-, Träger-, Konservierungsstoffe etc.In the manufacture of the dosage forms of the invention described above Preparations come with the current procedural guidelines for food technology logie or pharmaceutical technology to use, with regard to the selection suitable and approved auxiliaries, carriers, preservatives etc.
Die genannten Darreichungsformen der erfindungsgemäßen Zubereitungen stellen sicher, daß gesundheitsfördernde und/oder therapeutische Zufuhr- bzw. Dosierungsempfehlungen zu Polyphenolen vom Anwender regelmäßig umgesetzt werden können. Hier liegt ein wesentliches Unterscheidungsmerkmal der erfindungsgemäßen Zubereitungen etwa gegenüber der Anwendung von Grüntee-Blättern als Aufgußgetränk/Genußmittel. The dosage forms of the preparations according to the invention ensure that that health-promoting and / or therapeutic intake or dosage recommendations can be converted to polyphenols by the user regularly. Here is a essential distinguishing feature of the preparations according to the invention, for example compared to the use of green tea leaves as an infusion beverage.
Bei letzterem unterliegt die Konzentration der relevanten Wirkprinzipien (Polyphenole) breiten Schwankungen, die durch die individuelle Art der Teezubereitung bedingt sind. Die erfindungsgemäßen Zubereitungen z. B. aus Grüntee werden im Rahmen lebensmittel üblicher Zufuhrempfehlungen als Nahrungsergänzung, außerdem, nach Erfüllung der jeweils geltenden gesetzlichen Voraussetzungen, z. B. Normierung, Standardisierung, Zulassung, als Arzneimittel auf den Markt gebracht.In the latter, the concentration is subject to the relevant active principles (polyphenols) wide fluctuations caused by the individual way of making tea. The preparations according to the invention, for. B. from green tea are included in the food usual intake recommendations as a dietary supplement, moreover, after fulfilling the applicable legal requirements, e.g. B. standardization, standardization, Approval, launched as a drug.
Grüner Tee (Theae viridis folium) unterscheidet sich vom Schwarzen Tee (Theae nigrae
folium) nicht durch die Pflanze, sondern allein durch die unterschiedliche Aufbereitung der
Teeblätter. Der Hauptunterschied zwischen den beiden Teesorten besteht in der Fermen
tation. Zur Gewinnung des Schwarztees wird dieser einem Fermentationsprozeß
unterzogen, bei dem es vor allem zur Oxidation und Polimerisation der Polyphenole kommt.
Die Fermentation führt zu wesentlichen Veränderungen der Polyphenol-Funktionen.
Grünen Tee hingegen erhält man, indem die Fermente inaktiviert werden, und zwar durch
Erhitzen des frisch geernteten Materials für wenige Minuten in rotierenden zylindrischen Be
hältern mit gespanntem Wasserdampf oder in flachen eisernen Pfannen. Anschließend
wird maschinell etwa 30 Minuten gerollt, der Wassergehalt durch Trocknen auf 50% herab
gesetzt, nochmals gerollt und an der Sonne getrocknet. Grüner Tee liefert sehr helle, klare
und bitter schmeckende Aufgüsse. Bisher wurde Grüntee - wie Schwarztee - als Genußdroge
wegen seiner anregenden Wirkung getrunken. Diese ist im Coffein begründet, das anregend
auf das Zentralnervensystem wirkt. Neu wurde entdeckt, daß Grüntee mehrere Inhaltsstoffe
mit antioxidativer bzw. antikanzerogener Wirkung enthält. Unter den verschiedenen Inhalts
stoffen des Tees sind die Polyphenole für die Wissenschaft von zunehmendem Interesse.
Verantwortlich sind ihre offenbar gesundheitsfördernden bzw. -erhaltenden Eigenschaften.
Grüntee-Polyphenole sind in erster Linie Flavanole. ihre Molekülstruktur weist folgende
Besonderheiten auf:
Phenylchroman-Grundkörper weisen in den Positionen 5 und 7 Dihydroxylfunktionen auf;
zusammen mit dem Sauerstoff an Position 1 (Heterozyklus) führt dies zu einer hohen Nukleo
philie an den Positionen 6 und 8.Green tea (Theae viridis folium) differs from black tea (Theae nigrae folium) not in the plant, but only in the different preparation of the tea leaves. The main difference between the two types of tea is fermentation. To obtain the black tea, it is subjected to a fermentation process in which the polyphenols are primarily oxidized and polymerized. The fermentation leads to significant changes in the polyphenol functions. Green tea, on the other hand, is obtained by inactivating the fermentation, by heating the freshly harvested material for a few minutes in rotating cylindrical containers with tense steam or in flat iron pans. Then it is rolled by machine for about 30 minutes, the water content is reduced to 50% by drying, rolled again and dried in the sun. Green tea provides very bright, clear and bitter tasting infusions. So far, green tea - like black tea - has been drunk as a pleasure drug because of its stimulating effect. This is due to caffeine, which has a stimulating effect on the central nervous system. It has recently been discovered that green tea contains several ingredients with an antioxidative or anticarcinogenic effect. Among the various ingredients in tea, polyphenols are of increasing interest to science. Their apparently health-promoting or maintaining properties are responsible. Green tea polyphenols are primarily flavanols. their molecular structure has the following special features:
Phenylchroman bases have positions 5 and 7 of dihydroxyl functions; together with the oxygen at position 1 (heterocycle), this leads to a high nucleophile at positions 6 and 8.
Flavanole werden leicht zu korrespondierenden O-Quinonen oxidiert. Flavanole/Quinone fungieren als Wasserstoffakzeptor/Donator; sie interagieren mit reaktiven Sauerstoff- Spezies. Sie sind zur Chelatisierung von Metallionen fähig.Flavanols are easily oxidized to corresponding O-quinones. Flavanole / Quinone act as hydrogen acceptor / donor; they interact with reactive oxygen Species. They are capable of chelating metal ions.
In-vitro und in-vivo-Untersuchungen zufolge fungieren Polyphenole als Antioxidantien und Antagonisten verschiedenster Tumorpromotoren. Sie neutralisieren Mutagene sowie Kanzerogene; außerdem verzögern sie das Wachstum von einer Reihe von Tumoren. Für die Grüntee-Polyphenole (-)-Epicatechin-3-gallat und (-)-Epigallocatechin-3-gallat ist die Hemmung der HIV-1 reverse transcriptase belegt. Für die Enzym-Inhibition ist der Galloyl-Rest in Position 3 der genannte Grüntee-Polyphenole essentiell. According to in vitro and in vivo studies, polyphenols act as antioxidants and Antagonists of various tumor promoters. They neutralize mutagens as well Carcinogens; they also delay the growth of a number of tumors. For the green tea polyphenols (-) - epicatechin-3-gallate and (-) - epigallocatechin-3-gallate the inhibition of HIV-1 reverse transcriptase is proven. For the enzyme inhibition is the Galloyl residue in position 3 of the green tea polyphenols essential.
- - Bildung von Flavanol-Addukten mit elektrophilen Kanzerogenen (z. B. Inhibierung von Nitrosierungsreaktionen)- Formation of flavanol adducts with electrophilic carcinogens (e.g. inhibition of nitrosation reactions)
- - Verdrängung von Tumorpromotoren von Rezeptoren auf Zellmembranen- Displacement of tumor promoters from receptors on cell membranes
- - Inhibierung von tumorpromotorvermittelter Aktivierung von proliferationssteuernden Enzymen (z. B. Protein-Kinase-C, Ornithin-Decarboxylase)- Inhibition of tumor promoter-mediated activation of proliferation-controlling Enzymes (e.g. protein kinase-C, ornithine decarboxylase)
- - Inhibierung der reverse transcriptase von HIV-1 und anderer HIV-Typen, sowie sonstigen Enzymen und Strukturen von HIV-1 und anderer HIV-TypenInhibition of reverse transcriptase from HIV-1 and other HIV types, as well other enzymes and structures of HIV-1 and other types of HIV
- - Verminderung von oxidativem Streß- Reduction of oxidative stress
- -< Senkung der Virusreplikationsrate- <Reduce virus replication rate
- -< Einfluß auf den Transkriptionsfaktor NFkB- <influence on the transcription factor NFkB
- -< Erhöhung des intrazellulären Pools an reduziertem Glutathion- <increase in the intracellular pool of reduced glutathione
- - Nach derzeitigem Kenntnisstand liegt die therapeutische Dosierung der Polyphenole im Bereich von 300 mg bis 1200 mg pro Tag.- According to the current state of knowledge, the therapeutic dosage of the polyphenols lies in the range of 300 mg to 1200 mg per day.
Die erfindungsgemäße Zubereitung hat ein breites prophylaktisches, pharmakologisches, und therapeutisches Anwendungsgebiet, z. B.The preparation according to the invention has a broad prophylactic, pharmacological, and therapeutic area of application, e.g. B.
- - zur Prophylaxe und Therapie aller Zustände des oxidativen Stresses,- for the prophylaxis and therapy of all states of oxidative stress,
- - zur Prophylaxe und Therapie von Intoxikationen, die über Radikalreaktionen Schädigungen von biologischen Strukturen hervorrufen können,- for the prophylaxis and therapy of intoxications, via radical reactions Can cause damage to biological structures,
- - zur Prophylaxe und Therapie von Tumorerkrankungen jeder Genese und ihrer Vorstufen,- for the prophylaxis and therapy of tumor diseases of any genesis and their preliminary stages,
- - zur Prophylaxe und Therapie von Metastasen bei Tumorerkrankungen,- for the prophylaxis and therapy of metastases in tumor diseases,
- - zur Radikalentgiftung im Verlauf zytostatischer Chemotherapie,- for radical detoxification in the course of cytostatic chemotherapy,
- - zur Radikalentgiftung im Rahmen der Strahlentherapie in der Onkologie,- for radical detoxification as part of radiation therapy in oncology,
- - zur Prophylaxe und Therapie von Störungen der humoralen und zellulären Immunabwehr, z. B. bei Autoimmunerkrankungen, HIV, AIDS,- for the prophylaxis and therapy of disorders of the humoral and cellular Immune defense, e.g. B. in autoimmune diseases, HIV, AIDS,
- - zur Hemmung der reverse transcriptase von HIV-1 und anderer HIV-Typen, sowie sonstiger Enzyme und Strukturen von HIV-1 und anderer HIV-Typen,to inhibit the reverse transcriptase of HIV-1 and other types of HIV, as well as other enzymes and structures of HIV-1 and other types of HIV,
- - zur Prophylaxe und Therapie entzündlicher Erkrankungen jeder Genese,- for the prophylaxis and therapy of inflammatory diseases of any genesis,
- - zur Prophylaxe und Therapie von Lebererkrankungen.- for the prophylaxis and therapy of liver diseases.
- - zur Prophylaxe und Therapie von Infektionserkrankungen, ausgelöst durch Bakterien, Viren, Protozoen, etc., - for the prophylaxis and therapy of infectious diseases, triggered by Bacteria, viruses, protozoa, etc.,
- - zur unterstützenden Behandlung im Rahmen der medizinisch und/oder kosmetisch indizierten Reduktion des Körpergewichtes,- for supportive treatment in the context of medical and / or cosmetic indicated reduction in body weight,
- - zur Senkung des Blutzuckerspiegels,- to lower blood sugar levels,
- - zur Prophylaxe und Therapie der Hypercholesterinämie,- for the prophylaxis and therapy of hypercholesterolemia,
- - zur Senkung erhöhter Serum-Triglyceride,- to lower elevated serum triglycerides,
- - zur Verbesserung des atherogenen Index bei Personen mit kardiovasculären Risikofaktoren,- to improve the atherogenic index in people with cardiovascular Risk factors,
- - zur Prophylaxe und Therapie der Arteriosklerose,- for the prophylaxis and therapy of arteriosclerosis,
- - zur Verbesserung des Antioxidantienstatus bei Patienten mit Niereninsuffizienz, speziell bei Hämodialyse-Patienten mit eingeschränktem Ernährungsregime,- to improve the antioxidant status in patients with renal insufficiency, especially for hemodialysis patients with restricted nutritional regimes,
- - zur Prophylaxe und Verlangsamung des vorzeitigen Altersverschleißes aller Gewebe bei Lebensumständen, die zu vorzeitigem Altersverschleiß führen,- to prevent and slow the premature aging of all tissues in circumstances that lead to premature aging,
- - zur Prophylaxe und Therapie von Diarrhoen jeder Genese, zur Thrombozytenaggregationshemmung.- for the prophylaxis and therapy of diarrhea of any genesis, to inhibit platelet aggregation.
Claims (25)
enthaltend einen, mehrere bzw. alle der folgenden Stoffe:
(-)-Epicatechin.
(-)-Epigallocatechin.
(-)-Epicatechin-3-gallat,
(-)-Epigallocatechin-3-gallat,
Theaflavin (TF-1).
Theaflavin-monogallat A (TF-2A).
Theaflavin-monogallat B (TF-2B).
Theaflavin-digallat B (TF-3).
gewonnen aus
Camellia sinensis L. und/oder anderen pflanzlichen Ausgangsmaterialien und/oder durch partial-bzw. vollsynthetische Verfahren in Form von
Ganzdroge und/oder
Drogenteilen und/oder
Extrakten und/oder
isolierten Einzelstoffen und/oder deren Gemische und/oder
Derivaten isolierter Einzelstoffe und/oder deren Gemische und/oder
partial- bzw. vollsynthetisch hergestellten Stoffen und deren Derivate und/oder
Gemischen partial- bzw. vollsynthetisch hergestellter Stoffe und deren Derivate.
Im einzelnen werden die Zubereitungen gefertigt z. B. als
- - Pulver in abgeteilter und nicht abgeteilter Form
- - Granulat
- - Suspension
- - Tablette
- - Filmtablette
- - Kapsel
- - Dragee
- - Lösung zur enteralen und parenteralen Applikation
- - Extrakt
- - Pulverextrakt zur Bereitung einer Trinklösung
- - Suppositorium
- - Klistier
- - Salbe/Creme/Gel
containing one, several or all of the following substances:
(-) - Epicatechin.
(-) - Epigallocatechin.
(-) - epicatechin-3-gallate,
(-) - epigallocatechin-3-gallate,
Theaflavin (TF-1).
Theaflavin monogallate A (TF-2A).
Theaflavin monogallate B (TF-2B).
Theaflavin digallate B (TF-3).
obtained from
Camellia sinensis L. and / or other plant starting materials and / or by partial or. fully synthetic processes in the form of
Whole drug and / or
Drug parts and / or
Extracts and / or
isolated individual substances and / or their mixtures and / or
Derivatives of isolated individual substances and / or their mixtures and / or
partially or fully synthetic substances and their derivatives and / or
Mixtures of partially or fully synthetic substances and their derivatives.
In detail, the preparations are made e.g. B. as
- - Powder in divided and undivided form
- - granules
- - suspension
- - Tablet
- - film-coated tablet
- - capsule
- - Dragee
- - Solution for enteral and parenteral application
- - extract
- - Powder extract for the preparation of a drinking solution
- - suppository
- - Enema
- Ointment / cream / gel
oralen, enteralen, parenteralen, intramuskulären, intracutanen, subcutanen, externen, dermalen, nasalen, buccalen, sublingualen, vaginalen, rektalen Applikation, die, soweit erforderlich, reproduzierbare Umsetzung von Zufuhr- bzw. Dosierungsempfehlungen hinsichtlich eines oder mehrerer der beanspruchten Stoffe erlaubt. to
oral, enteral, parenteral, intramuscular, intracutaneous, subcutaneous, external, dermal, nasal, buccal, sublingual, vaginal, rectal application, which, if necessary, allows reproducible implementation of recommendations for dosing or administration of one or more of the claimed substances.
- - zur Prophylaxe und Therapie aller Zustände des oxidativen Stresses,
- - for the prophylaxis and therapy of all states of oxidative stress,
- - zur Prophylaxe und Therapie von Intoxikationen, die über Radikalkettenreaktionen Schädigungen von biologischen Strukturen hervorrufen können,
- - for the prophylaxis and therapy of intoxications, which can cause damage to biological structures via radical chain reactions,
- - zur Prophylaxe und Therapie von Tumorerkrankungen jeder Genese und ihrer Vorstufen,
- - for the prophylaxis and therapy of tumor diseases of any genesis and their preliminary stages,
- - zur Prophylaxe und Therapie von Metastasen bei Tumorerkrankungen.
- - for the prophylaxis and therapy of metastases in tumor diseases.
- - zur Radikalentgiftung im Verlauf zytostatischer Chemotherapie,
- - for radical detoxification in the course of cytostatic chemotherapy,
- - zur Radikalentgiftung im Rahmen der Strahlentherapie in der Onkologie,
- - for radical detoxification as part of radiation therapy in oncology,
- - zur Prophylaxe und Therapie von Störungen der humoralen und zellulären Immunabwehr, z. B. bei Autoimmunerkrankungen, HIV, AIDS,
- - For the prophylaxis and therapy of disorders of the humoral and cellular immune defense, e.g. B. in autoimmune diseases, HIV, AIDS,
- - zur Hemmung der HIV-1 reverse transcriptase und der anderer HlV-Typen, sowie sonstiger Enzyme und Strukturen von HIV-1 und anderer HIV-Typen,
- to inhibit HIV-1 reverse transcriptase and other HIV types, as well as other enzymes and structures of HIV-1 and other HIV types,
- - zur Prophylaxe und Therapie entzündlicher Erkrankungen jeder Genese.
- - for the prophylaxis and therapy of inflammatory diseases of any genesis.
- - zur Prophylaxe und Therapie von Lebererkrankungen.
- - for the prophylaxis and therapy of liver diseases.
- - zur Prophylaxe und Therapie von Infektionserkrankungen, ausgelöst durch Bakterien, Viren, Protozoen, Virionen, Prionen etc.
- - for the prophylaxis and therapy of infectious diseases caused by bacteria, viruses, protozoa, virions, prions etc.
- - zur unterstützenden Behandlung im Rahmen der medizinisch und/oder kosmetisch indizierten Reduktion des Körpergewichtes,
- - for supportive treatment as part of the medically and / or cosmetically indicated reduction in body weight,
- - zur Prophylaxe und Therapie der Hypercholesterinämie,
- - for the prophylaxis and therapy of hypercholesterolemia,
- - zur Senkung erhöhter Serum-Triglyceride,
- - to lower elevated serum triglycerides,
- - zur Verbesserung des atherogenen Index bei Personen mit kardiovasculären Risikofaktoren,
- - to improve the atherogenic index in people with cardiovascular risk factors,
- - zur Prophylaxe und Therapie der Arteriosklerose,
- - for the prophylaxis and therapy of arteriosclerosis,
- - zur Prophylaxe und Therapie von Störungen des Lipidstoffwechsels,
- - for the prophylaxis and therapy of disorders of lipid metabolism,
- - zur Prophylaxe und Therapie erhöhter Blutzuckerspiegel.
- - for the prophylaxis and therapy of high blood sugar levels.
- - zur Prophylaxe und Therapie erhöhten Blutdrucks,
- - for the prophylaxis and therapy of high blood pressure,
- - zur Verbesserung des Antioxidantienstatus bei Patienten mit Niereninsuffizienz, speziell bei Hämodialyse-Patienten mit eingeschränktem Ernährungsregime,
- - to improve the antioxidant status in patients with renal insufficiency, especially in hemodialysis patients with a restricted diet,
- - zur Prophylaxe und Verlangsamung des vorzeitigen Altersverschleißes aller Gewebe bei Lebensumständen, die zu vorzeitigem Altersverschleiß führen,
- - to prevent and slow the premature aging of all tissues in circumstances that lead to premature aging,
- - zur Prophylaxe und Therapie von Diarrhoen jeder Genese,
- - for the prophylaxis and therapy of diarrhea of any genesis,
- - zur Prophylaxe von Karies.
- - for the prevention of caries.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19627344A DE19627344A1 (en) | 1996-07-01 | 1996-07-01 | Therapeutic composition containing epicatechin and/or theaflavin |
| DE29623606U DE29623606U1 (en) | 1996-07-01 | 1996-07-01 | Therapeutically effective or health-promoting preparation from defined polyphenol compounds from green tea extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19627344A DE19627344A1 (en) | 1996-07-01 | 1996-07-01 | Therapeutic composition containing epicatechin and/or theaflavin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE19627344A1 true DE19627344A1 (en) | 1998-01-08 |
Family
ID=7799158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19627344A Ceased DE19627344A1 (en) | 1996-07-01 | 1996-07-01 | Therapeutic composition containing epicatechin and/or theaflavin |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE19627344A1 (en) |
Cited By (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0845264A1 (en) * | 1996-10-24 | 1998-06-03 | Emil Flachsmann AG | Partial or full extract of non fermentated Camellia sinensis L. |
| WO1999062478A1 (en) * | 1998-06-03 | 1999-12-09 | Beiersdorf Ag | Cosmetic or dermatologic preparations containing catechins or green tea extract |
| WO2001051048A1 (en) * | 2000-01-14 | 2001-07-19 | Color Access, Inc. | Use of epigallocatechin-gallate for inhibiting angiogenesis |
| FR2808192A1 (en) * | 2000-04-28 | 2001-11-02 | Oreal | EPICHATCHIN AS INHIBITOR OF NO-SYNTHASE AND USES |
| WO2000047193A3 (en) * | 1999-02-12 | 2001-12-06 | Karolinska Innovations Ab | Inhibition of angiogenesis with epigallocatechin-3-gallate |
| WO2002039956A2 (en) | 2000-11-15 | 2002-05-23 | Rutgers, The State University Of New Jersey | Black tea extract for prevention of disease |
| EP1100496A4 (en) * | 1998-07-21 | 2002-10-23 | Univ Jefferson | SMALL MOLECULES INHIBIT THE BCL-2 PROTEINS |
| WO2003002126A1 (en) * | 2001-06-28 | 2003-01-09 | University Of Pretoria | Anti-retroviral agent in combination with tea polyphenol for the treatment of viral infections |
| WO2003011339A1 (en) * | 2001-07-30 | 2003-02-13 | Dsm Ip Assets B.V. | Composition for epigallocatechin gallate |
| US6576660B1 (en) | 1997-10-31 | 2003-06-10 | Arch Development Corporation | Methods and compositions for regulation of 5-α-reductase activity |
| WO2003045328A3 (en) * | 2001-11-28 | 2003-10-09 | Nashai Biotech Llc | Methods of making and using theaflavin, theaflavin-3-gallate, theaflavin-3'-gallate and theaflavin 3,3'-digallate and mixtures thereof |
| WO2003086429A1 (en) * | 2002-04-16 | 2003-10-23 | Medestea Research & Production S.R.L. | A pharmaceutical formulation for endonasal administration and its use in the treatment of rhinitic symptoms |
| WO2003094878A1 (en) * | 2002-05-10 | 2003-11-20 | Suntory Limited | Gallocatechin gallate-containing composition |
| WO2002072086A3 (en) * | 2001-03-12 | 2004-02-19 | Consorzio Per Gli Studi Uni | Use of epigallocatechin-3-gallate or its derivatives in the prevention and treatment of neurodegenerative diseases |
| US6696484B2 (en) | 1997-10-31 | 2004-02-24 | University Of Chicago Office Of Technology And Intellectual Property | Method and compositions for regulation of 5-alpha reductase activity |
| WO2004084886A1 (en) * | 2003-03-28 | 2004-10-07 | Universidade Do Porto | THE USE OF BLOCKERS FOR THE LONG-TERM INHIBITION OF Na+-K+-ATPase AND/OR Na+/H+ EXCHANGE ACTIVITIES FOR THE PREPARATION OF A MEDICAMENT FOR THE INTESTINAL THERAPY |
| WO2004105779A3 (en) * | 2003-05-27 | 2005-03-17 | Cesare Montecucco | Green tea and oplyphenol inhibitors of bacterial proteases |
| WO2004112715A3 (en) * | 2003-06-20 | 2005-04-07 | Nashai Biotech Llc | Methods of making and using theaflavin,theaflavin-3-gallate, theaflavin-3’-gallate and theaflavin 3,3’ - digallate and mixtures thereof |
| US6929808B2 (en) * | 2000-11-03 | 2005-08-16 | Proteotech, Inc. | Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from Uncaria tomentosa and related plants |
| EP1764105A1 (en) * | 2005-09-20 | 2007-03-21 | Rentschler Arzneimittel GmbH | Use of tanning agents for the treatment of diarrhoea induced by chemotherapy |
| JP2007520449A (en) * | 2003-05-30 | 2007-07-26 | マテイアス・ラート | Nutritional composition and method for inhibiting smooth muscle cell contraction using the same |
| DE102006052915A1 (en) * | 2006-07-28 | 2008-01-31 | Humana Gmbh | Polyphenol peptide composition |
| WO2010066235A1 (en) | 2008-12-10 | 2010-06-17 | Christian-Albrechts-Universität Zu Kiel | Method for producing plant tissues suitable for consumption and having an increased content of quercetin and/or quercetin derivatives |
| WO2010072805A3 (en) * | 2008-12-24 | 2011-04-28 | Unilever Plc | Method and composition for skin color modulation |
| EP1883416A4 (en) * | 2005-05-24 | 2013-06-12 | Wellgen Inc | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING CONDITIONS ASSOCIATED WITH INFLAMMATION |
| EP2716167A1 (en) | 2012-10-02 | 2014-04-09 | Lunamed AG | Non-pharmaceutical composition comprising short chain fatty acids |
-
1996
- 1996-07-01 DE DE19627344A patent/DE19627344A1/en not_active Ceased
Non-Patent Citations (9)
| Title |
|---|
| Cancer Research 53(19), 1993, 4528-4533 * |
| Chem. Abstr. 111:160278 * |
| Chem. Abstr. 112:240477 * |
| Chem. Abstr. 115:214869 * |
| Chem. Abstr. 117:146347 * |
| Chem. Abstr. 121:163721 * |
| Chem. Abstr. 124:185534 * |
| Chem. Abstr. 124:37679 * |
| Thromb. Haemostasis 75(6), 1996, 945-949 * |
Cited By (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0845264A1 (en) * | 1996-10-24 | 1998-06-03 | Emil Flachsmann AG | Partial or full extract of non fermentated Camellia sinensis L. |
| US6576660B1 (en) | 1997-10-31 | 2003-06-10 | Arch Development Corporation | Methods and compositions for regulation of 5-α-reductase activity |
| US6696484B2 (en) | 1997-10-31 | 2004-02-24 | University Of Chicago Office Of Technology And Intellectual Property | Method and compositions for regulation of 5-alpha reductase activity |
| WO1999062478A1 (en) * | 1998-06-03 | 1999-12-09 | Beiersdorf Ag | Cosmetic or dermatologic preparations containing catechins or green tea extract |
| EP1100496A4 (en) * | 1998-07-21 | 2002-10-23 | Univ Jefferson | SMALL MOLECULES INHIBIT THE BCL-2 PROTEINS |
| WO2000047193A3 (en) * | 1999-02-12 | 2001-12-06 | Karolinska Innovations Ab | Inhibition of angiogenesis with epigallocatechin-3-gallate |
| WO2001051048A1 (en) * | 2000-01-14 | 2001-07-19 | Color Access, Inc. | Use of epigallocatechin-gallate for inhibiting angiogenesis |
| FR2808192A1 (en) * | 2000-04-28 | 2001-11-02 | Oreal | EPICHATCHIN AS INHIBITOR OF NO-SYNTHASE AND USES |
| US6929808B2 (en) * | 2000-11-03 | 2005-08-16 | Proteotech, Inc. | Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from Uncaria tomentosa and related plants |
| US7285293B2 (en) * | 2000-11-03 | 2007-10-23 | Gerardo Castillo | Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from Uncaria tomentosa and related plants |
| US7238376B2 (en) * | 2000-11-15 | 2007-07-03 | Rutgers, The State University | Black tea extract for prevention of disease |
| EP1349560A4 (en) * | 2000-11-15 | 2008-02-20 | Univ Rutgers | EXTRACT OF BLACK TEA FOR DISEASE PREVENTION |
| WO2002039956A2 (en) | 2000-11-15 | 2002-05-23 | Rutgers, The State University Of New Jersey | Black tea extract for prevention of disease |
| WO2002072086A3 (en) * | 2001-03-12 | 2004-02-19 | Consorzio Per Gli Studi Uni | Use of epigallocatechin-3-gallate or its derivatives in the prevention and treatment of neurodegenerative diseases |
| WO2003002126A1 (en) * | 2001-06-28 | 2003-01-09 | University Of Pretoria | Anti-retroviral agent in combination with tea polyphenol for the treatment of viral infections |
| WO2003011339A1 (en) * | 2001-07-30 | 2003-02-13 | Dsm Ip Assets B.V. | Composition for epigallocatechin gallate |
| US8039510B2 (en) | 2001-11-28 | 2011-10-18 | Nashai Biotech, Llc | Methods of making and using theaflavin, theaflavin-3-gallate, theaflavin-3′-gallate and theaflavin 3,3′-digallate and mixtures thereof |
| US7427622B2 (en) | 2001-11-28 | 2008-09-23 | Nashai Biotech, Llc | Method of making and using theaflavin, theaflavin-3-gallate, theaflavin-3′-gallate and theaflavin 3,3′-digallate and mixtures thereof |
| US7157493B2 (en) | 2001-11-28 | 2007-01-02 | Nashai Biotech, Llc | Methods of making and using theaflavin, theaflavin-3-gallate, theaflavin-3′-gallate and theaflavin 3,3′-digallate and mixtures thereof |
| WO2003045328A3 (en) * | 2001-11-28 | 2003-10-09 | Nashai Biotech Llc | Methods of making and using theaflavin, theaflavin-3-gallate, theaflavin-3'-gallate and theaflavin 3,3'-digallate and mixtures thereof |
| WO2003086429A1 (en) * | 2002-04-16 | 2003-10-23 | Medestea Research & Production S.R.L. | A pharmaceutical formulation for endonasal administration and its use in the treatment of rhinitic symptoms |
| WO2003094878A1 (en) * | 2002-05-10 | 2003-11-20 | Suntory Limited | Gallocatechin gallate-containing composition |
| WO2004084886A1 (en) * | 2003-03-28 | 2004-10-07 | Universidade Do Porto | THE USE OF BLOCKERS FOR THE LONG-TERM INHIBITION OF Na+-K+-ATPase AND/OR Na+/H+ EXCHANGE ACTIVITIES FOR THE PREPARATION OF A MEDICAMENT FOR THE INTESTINAL THERAPY |
| WO2004105779A3 (en) * | 2003-05-27 | 2005-03-17 | Cesare Montecucco | Green tea and oplyphenol inhibitors of bacterial proteases |
| JP2007520449A (en) * | 2003-05-30 | 2007-07-26 | マテイアス・ラート | Nutritional composition and method for inhibiting smooth muscle cell contraction using the same |
| EP1628658A4 (en) * | 2003-05-30 | 2007-09-05 | Matthias Rath | FUNCTIONAL COMPOSITION AND METHOD FOR INHIBITING CONTRACTION OF SMOOTH MUSCLE CELLS |
| WO2004112715A3 (en) * | 2003-06-20 | 2005-04-07 | Nashai Biotech Llc | Methods of making and using theaflavin,theaflavin-3-gallate, theaflavin-3’-gallate and theaflavin 3,3’ - digallate and mixtures thereof |
| EP1883416A4 (en) * | 2005-05-24 | 2013-06-12 | Wellgen Inc | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING CONDITIONS ASSOCIATED WITH INFLAMMATION |
| EP1764105A1 (en) * | 2005-09-20 | 2007-03-21 | Rentschler Arzneimittel GmbH | Use of tanning agents for the treatment of diarrhoea induced by chemotherapy |
| WO2008012089A3 (en) * | 2006-07-28 | 2008-03-27 | Humana Milchunion Eg | Polyphenol/peptide composition and use thereof for promoting gastric health |
| EA015701B1 (en) * | 2006-07-28 | 2011-10-31 | Хумана Мильхунион Эг | Polyphenol/peptide composition comprising epicatechin and glycomacropeptide from lactoserum, process for the preparation thereof and use composition for promoting gastric health |
| DE102006052915A1 (en) * | 2006-07-28 | 2008-01-31 | Humana Gmbh | Polyphenol peptide composition |
| WO2010066235A1 (en) | 2008-12-10 | 2010-06-17 | Christian-Albrechts-Universität Zu Kiel | Method for producing plant tissues suitable for consumption and having an increased content of quercetin and/or quercetin derivatives |
| DE102008061248A1 (en) | 2008-12-10 | 2010-06-24 | Christian-Albrechts-Universität Zu Kiel | Process for the preparation of vegetable tissue suitable for consumption with an increased content of quercetin and / or quercetin derivatives |
| WO2010072805A3 (en) * | 2008-12-24 | 2011-04-28 | Unilever Plc | Method and composition for skin color modulation |
| EP2716167A1 (en) | 2012-10-02 | 2014-04-09 | Lunamed AG | Non-pharmaceutical composition comprising short chain fatty acids |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE19627344A1 (en) | Therapeutic composition containing epicatechin and/or theaflavin | |
| JP3983003B2 (en) | Glutathione enhancing composition | |
| EP2859896A1 (en) | Pharmaceutical compositions for the treatment of muscular disorders | |
| WO2016192507A1 (en) | Composition having whitening effect and application thereof | |
| KR20090012565A (en) | Hair loss prevention and hair growth promoting composition containing a natural extract | |
| CN106923115A (en) | Plant beverage containing west safflower and its preparation method and application | |
| CN106617049A (en) | Propolis healthcare product with moringa oleifera leaf extract and method for preparing propolis healthcare product | |
| JP2006348053A (en) | Glutathione enhancing composition | |
| KR102322276B1 (en) | Beverage composition for preventing obesity and relieving edema | |
| JP2006348052A (en) | Glutathione enhancing composition | |
| JP2001233727A (en) | Cosmetics | |
| Sharma et al. | Green Tea in Green World an updated review | |
| JP2004352626A (en) | Anti-cholesterol agent containing plant-derived components | |
| KR100885478B1 (en) | Natural whitening composition with antioxidant function | |
| KR100883773B1 (en) | Cosmetic composition comprising as an active ingredient salted fermented extract of citron or citrus fruit | |
| DE29623606U1 (en) | Therapeutically effective or health-promoting preparation from defined polyphenol compounds from green tea extract | |
| CN1232690A (en) | Healthy ginkgo-sea buckthorn tea | |
| US20100247670A1 (en) | Red Grape Dry Composition and Health Tea | |
| KR101757457B1 (en) | Cosmetic composition containing natural complex extract for anti-thermal skin aging and skin soothing | |
| KR20140036966A (en) | Composition for improving exercise capacity or a composition for reducing fatigue using leaves of sasa quelpaertensis | |
| CN110538308B (en) | Traditional Chinese medicine composition for hair growth and preparation method thereof | |
| CN102308989B (en) | Health care composition of formica rufa, grape and propolis extracts | |
| KR102175244B1 (en) | antioxidant composition comprising Astragalus membranaceus and method of manufacturing the same | |
| KR20120020996A (en) | Herb seed extract having antioxidant, whitening activity and atopy improvement effect and cosmetic compound comprised the same | |
| KR102601729B1 (en) | Manufacturing method composition for improving male sexual function |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| 8125 | Change of the main classification |
Ipc: A61K 35/78 |
|
| 8131 | Rejection |